In our study, we examined the impact of inhibitory KIR–HLA ligand interactions at the genomic level and found that NK cell potency against GBM was influenced by the presence of licensed KIR encountering cognate HLA ligands in the patients’ tumor, thereby calibrating their efficacy. This evidence concerns the gene KIR3DL1 and glioblastoma.